UNLIMITED TURBO SHORT - ELI LILLY & CO | Real-time Euronext Paris 07:47:27 2024-07-11 am EDT | ||
| 2.723 EUR | +3.69% |
|
| Current month | -19.96% | ||
| 1 month | -37.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 2.723 | +3.69% |
| 24-07-10 | 2.626 | -12.76% |
| 24-07-09 | 3.01 | -3.53% |
| 24-07-08 | 3.12 | -2.26% |
| 24-07-05 | 3.192 | -6.01% |
Real-time Euronext Paris
Last update July 11, 2024 at 07:47 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| 1F5OB | |
| ISIN | NLBNPNL2S6R8 |
| Date issued | 2024-05-23 |
| Strike | 1,072 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 4.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.46 € |
|---|---|
| Lowest since issue | 2.602 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
877.2
USD
Spread / Average Target
-6.66%
- Stock Market
- Certificates
- 1F5OB Certificat
